MORPHOSYS Share Price Swiss Exchange
Equities
OXMOR
DE0006632003
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
65.32 EUR | 0.00% | 0.00% | 0.00% |
12:32pm | Morphosys says takeover by Novartis on course after report of drug safety concern | RE |
04-11 | Health Care Slips on Risk Bias -- Health Care Roundup | DJ |
Sales 2024 * | 252M 270M 21.49B | Sales 2025 * | 325M 348M 27.76B | Capitalization | 2.56B 2.74B 218B |
---|---|---|---|---|---|
Net income 2024 * | -182M -195M -15.55B | Net income 2025 * | -115M -123M -9.83B | EV / Sales 2024 * | 9.74 x |
Net cash position 2024 * | 106M 114M 9.05B | Net cash position 2025 * | 241M 258M 20.55B | EV / Sales 2025 * | 7.12 x |
P/E ratio 2024 * |
-16
x | P/E ratio 2025 * |
-32.9
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.59% |
Latest transcript on MORPHOSYS
Managers | Title | Age | Since |
---|---|---|---|
Jean-Paul Kress
CEO | Chief Executive Officer | 59 | 31/08/19 |
Lucinda Crabtree
DFI | Director of Finance/CFO | 45 | 06/08/23 |
Luisa Ciccarelli
CTO | Chief Tech/Sci/R&D Officer | - | 31/07/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Brosnan
BRD | Director/Board Member | 69 | 16/05/18 |
Director/Board Member | 67 | 16/05/18 | |
Marc Cluzel
CHM | Chairman | 69 | 30/05/12 |
1st Jan change | Capi. | |
---|---|---|
+2.08% | 42.75B | |
+47.70% | 41.61B | |
+12.39% | 41.34B | |
-12.36% | 26.59B | |
+8.75% | 25.49B | |
-23.35% | 18.12B | |
+30.90% | 12.24B | |
-1.82% | 11.76B | |
+8.72% | 11B |
- Stock Market
- Equities
- MOR Stock
- OXMOR Stock